The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 14 results:
Author Title Type [ Year(Asc)]
Filters: Author is Gavriatopoulou, Maria  [Clear All Filters]
2018
Gavriatopoulou, M., Kastritis E., Ntanasis-Stathopoulos I., Fotiou D., Roussou M., Migkou M., et al. (2018).  The addition of IMiDs for patients with daratumumab-refractory multiple myeloma can overcome refractoriness to both agents.. Blood. 131(4), 464-467.
Ziogas, D. C., Terpos E., Gavriatopoulou M., Migkou M., Fotiou D., Roussou M., et al. (2018).  Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional cases.. Leuk Lymphoma. 59(4), 983-987.
Bagratuni, T., Ntanasis-Stathopoulos I., Gavriatopoulou M., Mavrianou-Koutsoukou N., Liacos C., Patseas D., et al. (2018).  Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies.. Leukemia.
Kastritis, E., Kostopoulos I. V., Terpos E., Paiva B., Fotiou D., Gavriatopoulou M., et al. (2018).  Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.. Blood Cancer J. 8(5), 46.
Kastritis, E., Papassotiriou I., Merlini G., Milani P., Terpos E., Basset M., et al. (2018).  Growth differentiation factor-15 is a new biomarker for survival and renal outcomes in light chain amyloidosis.. Blood. 131(14), 1568-1575.
Katodritou, E., Terpos E., Delimpasi S., Kotsopoulou M., Michalis E., Vadikolia C., et al. (2018).  Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.. Blood Cancer J. 8(3), 31.

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.